Translational Solutions
The Eclosion Foundation, Chemin des Aulx…
Joined March 2016
- Tweets13
- Following24
- Followers8
- Likes20
Pinned Tweet
Translational medicine in action, and validation for the MesenFlow strategy. Mesenchymal factors regulate human CD16+ monocyte function in chronic inflammation and cancer. teapaw.org/NatureComms/status/957…
Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours
go.nature.com/2DHO56P
MesenFlow Technologies is proud to be part of a study on circadian rhythms in leukocyte trafficking, published in @ImmunityCP. What a fantastic way to end the year.
We wish our friends and colleagues a Happy New Year for 2019!
cell.com/immunity/pdfExtende…
Commentary on the publication in Nature Comms, with the founders of MesenFlow Technologies. Applying powerful and deliverable translational technologies to cancer therapy. sciencedaily.com/releases/20…
Valdiating a translational approach in the treatment of cancer & chronic inflammation. A radio interview with author Adama Sidibe about a recent publication in Nature Comms. Further validation of the MesenFlow strategy (In French). rts.ch/play/radio/cqfd/audio… via @RadioTeleSuisse
MesenFlow retweeted
Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours
go.nature.com/2DHO56P
I'm going to CPhI Worldwide, 24-26 Oct, Messe Frankfurt, Germany. Join me! invt.io/8F062F224C @CPhIWW #cphiww
Setting up our stand. MesenFlow Technologies is at the ESM-EVBO 2017 conference in Geneva. Looking forward to seeing you there!
MesenFlow will be at the ESM-EVBO 2017, May 29-June 1st 2017, Geneva, Switzerland esm-evbo2017.org
